ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Fight Back! Win the War Being Waged Against Your Immune System

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Acupressure reduced fatigue in breast cancer survivors

Omega-3 fatty acid stops known trigger of lupus

What’s Fenugreek Good For?

Print Page
Email Article

FDA Grants Pharmos Brain-Injury Drug Fast-Track Status

  [ 108 votes ]   [ Discuss This Article ] • October 2, 2003

By Roger Cheng

NEW YORK -- Shares of Pharmos Corp. (NasdaqSC:PARS - News) surged Tuesday and hit a 52-week high after regulators awarded its traumatic brain-injury drug fast-track status.

Pharmos's dexanabinol, which treats secondary neuroprotective brain damage following injury, won fast-track status from the Food and Drug Administration (News - Websites). The designation is given to drugs that treat serious and life-threatening conditions for which no other approved treatments exist.

Primary brain damage, which stems from something such as a violent impact, precipitates the secondary injury, said Pharmos spokeswoman Gale Smith. The secondary damage involves a neurotoxic cascade which causes molecular deterioration, leading to ailments such as memory loss and ultimately a coma.

Aside from the neurotoxic cascade, the injury includes inflammation, which pressures the brain, she said. Dexanabinol works on three different levels to control the inflammation and neurotoxic cascade, she said.

The company estimates the U.S. market for patients with traumatic brain injury to be more than $500 million. The international market potential may exceed $1 billion.

While dexanabinol's critical Phase III trial began in early 2001, Pharmos is on the cusp of the advanced trials for Phase III, which test efficacy, Ms. Smith said. The company expects Phase III trials to wrap up in the second half of 2004.

Around 12:15 p.m. on the Nasdaq Stock Market (News - Websites), shares of Pharmos were up 67 cents, or 33%, to $2.68 after hitting an intraday high of $2.95. The previous 52-week high of $2.65 was set on June 11.

Along with the FDA news, Pharmos also completed a $21 million convertible debt offering to shore up its cash reserve and prepare itself for potential acquisitions. The offering also cleared up a possible violation of Nasdaq's corporate governance rules.

Nasdaq has a problem with the company's March and May equity offerings, said Chief Financial Officer Bob Cook. The offerings represented more than 20% of existing shares, and the exchange felt the company should have gotten shareholder approval. The current deal is structured so, when grouped together with the prior offerings, it meets Nasdaq's regulations.

"While we didn't agree with (Nasdaq's claim), we worked out a way to drop the issue," Mr. Cook said. "This issue has gone."

He noted the issue never became a formal inquiry, and added the company didn't have to pay any penalties.

A spokesman for Nasdaq couldn't immediately be reached for comment.

The deal followed two prior offerings that have raised enough cash to take the company through 2004, said Mr. Cook. The company's projected 2003 operating expense is about $15 million, and the company hasn't provided guidance for its expense estimate in 2004.

While Pharmos has enough cash to run through the trial and FDA new-drug application for dexanabinol, Mr. Cook wouldn't rule out any future offerings. He also noted the company would be receiving about $10 million in royalty payments from partner Bausch & Lomb Inc. (NYSE:BOL - News) .

As part of the current deal, $16 million of the $21 million raised will be reserved for acquisitions only. Mr. Cook said the company doesn't have any immediate plans on the horizon.

Source: Dow Jones Business News.

Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Live Without Anxiety or Stress Live Without Anxiety or Stress
When a Negative is Positive - Goodnighties Recovery Sleepwear When a Negative is Positive - Goodnighties Recovery Sleepwear
Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
Eating Fat is Good... Maybe... Could Be... Sometimes Eating Fat is Good... Maybe... Could Be... Sometimes

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map